SPECTACL: SPECTroscopic Assessment of Coronary Lipid

Inclusion Criteria: * \>=18yrs and undergoing elective or non-emergent PCI of a de novo native coronary artery lesion * Treatment plan (at time of consent and at time of intervention) must be to perform an intervention on no more than 2 lesions, where one is the culprit lesion and the other lesion requires revascularization at the discretion of the treating physician. * Target lesion should have "low-risk" characteristics(defined by angiography) * Subject must be able to read, understand and sign an approved informed consent form and follow protocol * Female subjects of child bearing potential must have a negative serum pregnancy test prior to enrollment Exclusion Criteria: * Evidence of Clinical instability in the 6 hours before the procedure, or at any time during the procedure (72 hours stable post-STEMI) * Angiographically Unsuitable Coronary and/or Lesion Morphology in the culprit vessel. * A contraindication to anticoagulation or increased risk of bleeding. * Clinically significant abnormal laboratory findings * Presence of a drug eluting stent in the artery for experimental study prior to NIR measurement, unless all struts are covered by endothelium as documented by IVUS * Elective PCI on or through bypass grafts or LIMA grafts * Allergy or intolerance to aspirin or clopidogrel * Planned use of laser ablation, rotational ablation, brachytherapy, or atherectomy device * Enrollment or participation in any other medication trial within the previous 30 days * Current enrollment participation or enrolled in another clinical trial * Any other factor that the investigator feels would put the patient at increased risk if participating in the protocol